Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
330 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Epilepsy - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Epilepsy - Pipeline Review, H1 2015', provides an overview of the Epilepsy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Epilepsy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Epilepsy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Epilepsy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epilepsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 10 Global Markets Direct Report Coverage 10 Epilepsy Overview 11 Therapeutics Development 12 Pipeline Products for Epilepsy - Overview 12 Pipeline Products for Epilepsy - Comparative Analysis 13 Epilepsy - Therapeutics under Development by Companies 14 Epilepsy - Therapeutics under Investigation by Universities/Institutes 20 Epilepsy - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Unknown Stage Products 25 Epilepsy - Products under Development by Companies 26 Epilepsy - Products under Investigation by Universities/Institutes 35 Epilepsy - Companies Involved in Therapeutics Development 37 Acorda Therapeutics, Inc. 37 Adamas Pharmaceuticals, Inc. 38 Advicenne Pharma 39 Aeolus Pharmaceuticals, Inc. 40 Aestus Therapeutics, Inc. 41 Alexza Pharmaceuticals, Inc. 42 Allergan, Inc. 43 Anavex Life Sciences Corp. 44 Asklepios BioPharmaceutical, Inc. 45 Astellas Pharma Inc. 46 Bial - Portela & Ca, S.A. 47 BioCrea GmbH 48 Bionomics Limited 49 Biovista Inc. 50 Catalyst Pharmaceutical Partners, Inc. 51 Celentyx Ltd. 52 Chong Kun Dang Pharmaceutical Corp. 53 Concert Pharmaceuticals, Inc. 54 Convergence Pharmaceuticals Ltd. 55 D-Pharm Ltd. 56 Desitin Arzneimittel GmbH 57 Eisai Co., Ltd. 58 Epirus Biopharmaceuticals, Inc. 59 Glialogix, Inc. 60 GW Pharmaceuticals plc 61 H. Lundbeck A/S 62 INSYS Therapeutics, Inc. 63 Iproteos S.L. 64 Knopp Biosciences LLC 65 Ligand Pharmaceuticals, Inc. 66 Lipicard Technologies Limited 67 Lohocla Research Corporation 68 Marathon Pharmaceuticals, LLC 69 MarcoPolo Pharmaceuticals SA 70 Marinus Pharmaceuticals, Inc. 71 MedGenesis Therapeutix Inc. 72 Neurocrine Biosciences, Inc. 73 Novartis AG 74 Pfizer Inc. 75 PharmatrophiX, Inc. 76 RestorGenex Corporation 77 Retrophin Inc. 78 Sage Therapeutics 79 Saniona AB 80 SciFluor Life Sciences, LLC 81 SK Biopharmaceuticals Co., Ltd. 82 UCB S.A. 83 Ultragenyx Pharmaceutical Inc. 84 Upsher-Smith Laboratories, Inc. 85 Vichem Chemie Research Ltd. 86 VistaGen Therapeutics, Inc. 87 Zynerba Pharmaceuticals, Inc. 88 Epilepsy - Therapeutics Assessment 89 Assessment by Monotherapy Products 89 Assessment by Target 90 Assessment by Mechanism of Action 95 Assessment by Route of Administration 100 Assessment by Molecule Type 102 Drug Profiles 104 2-DG - Drug Profile 104 ADD-405008 - Drug Profile 106 ADS-8800 Series - Drug Profile 107 ADV-5803 - Drug Profile 108 ADV-6208 - Drug Profile 109 ADV-6769 - Drug Profile 110 ADV-6770 - Drug Profile 111 AEOL-1114B - Drug Profile 112 AEOL-11203 - Drug Profile 113 AEOL-11207 - Drug Profile 114 alprazolam - Drug Profile 116 ANAVEX-2-73 - Drug Profile 118 AV-101 - Drug Profile 119 AVL-5189 - Drug Profile 120 BNP-TLE - Drug Profile 121 brivaracetam - Drug Profile 122 BVA-601 - Drug Profile 124 C-10068 - Drug Profile 125 cannabidiol - Drug Profile 126 carbamazepine - Drug Profile 127 carisbamate - Drug Profile 129 CCG-63802 - Drug Profile 131 Cell Therapy for Parkinson's Disease and Epilepsy - Drug Profile 132 CHEC-9 - Drug Profile 133 CKD-903 - Drug Profile 135 CNV-1061436 - Drug Profile 136 cosyntropin - Drug Profile 137 CPP-115 - Drug Profile 138 CX-1010 - Drug Profile 140 diazepam - Drug Profile 141 diazepam - Drug Profile 142 diazepam - Drug Profile 143 DP-VPA - Drug Profile 145 Drug for Epilepsy - Drug Profile 147 Drug to Agonize GABA Receptor for Epilepsy - Drug Profile 148 Drugs to Inhibit MAPK for Epilepsy and Behavioral Disorders - Drug Profile 149 EMSP - Drug Profile 150 Epidiolex - Drug Profile 151 ESB - Drug Profile 153 ESBB - Drug Profile 154 eslicarbazepine acetate - Drug Profile 155 everolimus - Drug Profile 158 fosphenytoin sodium - Drug Profile 163 FV-082 - Drug Profile 164 FV-137 - Drug Profile 165 ganaxolone - Drug Profile 166 Gene Therapy to Activate Neuropeptide Y Receptor Y2 and Y5 for Epilepsy - Drug Profile 168 GLX-1112 - Drug Profile 169 GWP-42003-P - Drug Profile 170 GWP-42006 - Drug Profile 171 IPR-003 - Drug Profile 172 KM-113 - Drug Profile 173 KM-314 - Drug Profile 174 lacosamide - Drug Profile 175 lamotrigine - Drug Profile 180 levetiracetam - Drug Profile 181 levetiracetam - Drug Profile 184 liatermin - Drug Profile 185 LT-4121 - Drug Profile 188 LT-4122 - Drug Profile 189 LT-4123 - Drug Profile 190 LT-4124 - Drug Profile 191 LT-4125 - Drug Profile 192 LT-4126 - Drug Profile 193 MB-003 - Drug Profile 194 midazolam hydrochloride - Drug Profile 195 MRS-5474 - Drug Profile 196 MSP - Drug Profile 197 naluzotan - Drug Profile 198 NB-23R1 - Drug Profile 199 NGT-168 - Drug Profile 200 P-529 - Drug Profile 201 perampanel - Drug Profile 203 PF-04895162 - Drug Profile 206 PRTT-200 - Drug Profile 207 Remegal - Drug Profile 208 rufinamide - Drug Profile 209 SAGE-217 - Drug Profile 211 SAGE-547 - Drug Profile 212 SAGE-689 - Drug Profile 214 SCT-66 - Drug Profile 215 selurampanel - Drug Profile 216 SF-0034 - Drug Profile 218 SGE-102 - Drug Profile 219 Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 220 Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 221 Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile 222 Small Molecule for Central Nervous System - Drug Profile 223 Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain - Drug Profile 225 Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy - Drug Profile 226 Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders - Drug Profile 227 Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 228 Small Molecules for CNS Disorders - Drug Profile 229 Small Molecules for Epilepsy - Drug Profile 230 Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS - Drug Profile 232 Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 233 Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 234 Small Molecules to Agonize GABA-A Receptor For Epilepsy - Drug Profile 236 Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 237 Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 238 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 239 Small Molecules to Inhibit Dynamin for Epilepsy and Oncology - Drug Profile 240 sulthiame - Drug Profile 241 TG-4155 - Drug Profile 242 tonabersat - Drug Profile 243 topiramate - Drug Profile 244 UBP-608 - Drug Profile 245 UX-007 - Drug Profile 246 VAD-1 - Drug Profile 247 VAD-2 - Drug Profile 248 VB-3323 - Drug Profile 249 VID-45110 - Drug Profile 250 VLB-01 - Drug Profile 251 VU-0456810 - Drug Profile 252 YKP-3089 - Drug Profile 253 Z-944 - Drug Profile 255 ZYN-002 - Drug Profile 256 Epilepsy - Recent Pipeline Updates 257 Epilepsy - Dormant Projects 303 Epilepsy - Discontinued Products 309 Epilepsy - Product Development Milestones 311 Featured News & Press Releases 311 Appendix 321 Methodology 321 Coverage 321 Secondary Research 321 Primary Research 321 Expert Panel Validation 321 Contact Us 321 Disclaimer 322
List of Tables Number of Products under Development for Epilepsy, H1 2015 20 Number of Products under Development for Epilepsy - Comparative Analysis, H1 2015 21 Number of Products under Development by Companies, H1 2015 23 Number of Products under Development by Companies, H1 2015 (Contd..1) 24 Number of Products under Development by Companies, H1 2015 (Contd..2) 25 Number of Products under Development by Companies, H1 2015 (Contd..3) 26 Number of Products under Development by Companies, H1 2015 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H1 2015 29 Comparative Analysis by Late Stage Development, H1 2015 30 Comparative Analysis by Clinical Stage Development, H1 2015 31 Comparative Analysis by Early Stage Development, H1 2015 32 Comparative Analysis by Unknown Stage Development, H1 2015 33 Products under Development by Companies, H1 2015 34 Products under Development by Companies, H1 2015 (Contd..1) 35 Products under Development by Companies, H1 2015 (Contd..2) 36 Products under Development by Companies, H1 2015 (Contd..3) 37 Products under Development by Companies, H1 2015 (Contd..4) 38 Products under Development by Companies, H1 2015 (Contd..5) 39 Products under Development by Companies, H1 2015 (Contd..6) 40 Products under Development by Companies, H1 2015 (Contd..7) 41 Products under Development by Companies, H1 2015 (Contd..8) 42 Products under Investigation by Universities/Institutes, H1 2015 43 Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 44 Epilepsy - Pipeline by Acorda Therapeutics, Inc., H1 2015 45 Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 46 Epilepsy - Pipeline by Advicenne Pharma, H1 2015 47 Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 48 Epilepsy - Pipeline by Aestus Therapeutics, Inc., H1 2015 49 Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H1 2015 50 Epilepsy - Pipeline by Allergan, Inc., H1 2015 51 Epilepsy - Pipeline by Anavex Life Sciences Corp., H1 2015 52 Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2015 53 Epilepsy - Pipeline by Astellas Pharma Inc., H1 2015 54 Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H1 2015 55 Epilepsy - Pipeline by BioCrea GmbH, H1 2015 56 Epilepsy - Pipeline by Bionomics Limited, H1 2015 57 Epilepsy - Pipeline by Biovista Inc., H1 2015 58 Epilepsy - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 59 Epilepsy - Pipeline by Celentyx Ltd., H1 2015 60 Epilepsy - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 61 Epilepsy - Pipeline by Concert Pharmaceuticals, Inc., H1 2015 62 Epilepsy - Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 63 Epilepsy - Pipeline by D-Pharm Ltd., H1 2015 64 Epilepsy - Pipeline by Desitin Arzneimittel GmbH, H1 2015 65 Epilepsy - Pipeline by Eisai Co., Ltd., H1 2015 66 Epilepsy - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 67 Epilepsy - Pipeline by Glialogix, Inc., H1 2015 68 Epilepsy - Pipeline by GW Pharmaceuticals plc, H1 2015 69 Epilepsy - Pipeline by H. Lundbeck A/S, H1 2015 70 Epilepsy - Pipeline by INSYS Therapeutics, Inc., H1 2015 71 Epilepsy - Pipeline by Iproteos S.L., H1 2015 72 Epilepsy - Pipeline by Knopp Biosciences LLC, H1 2015 73 Epilepsy - Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 74 Epilepsy - Pipeline by Lipicard Technologies Limited, H1 2015 75 Epilepsy - Pipeline by Lohocla Research Corporation, H1 2015 76 Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H1 2015 77 Epilepsy - Pipeline by MarcoPolo Pharmaceuticals SA, H1 2015 78 Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 79 Epilepsy - Pipeline by MedGenesis Therapeutix Inc., H1 2015 80 Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H1 2015 81 Epilepsy - Pipeline by Novartis AG, H1 2015 82 Epilepsy - Pipeline by Pfizer Inc., H1 2015 83 Epilepsy - Pipeline by PharmatrophiX, Inc., H1 2015 84 Epilepsy - Pipeline by RestorGenex Corporation, H1 2015 85 Epilepsy - Pipeline by Retrophin Inc., H1 2015 86 Epilepsy - Pipeline by Sage Therapeutics, H1 2015 87 Epilepsy - Pipeline by Saniona AB, H1 2015 88 Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H1 2015 89 Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 90 Epilepsy - Pipeline by UCB S.A., H1 2015 91 Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2015 92 Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H1 2015 93 Epilepsy - Pipeline by Vichem Chemie Research Ltd., H1 2015 94 Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H1 2015 95 Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 96 Assessment by Monotherapy Products, H1 2015 97 Number of Products by Stage and Target, H1 2015 99 Number of Products by Stage and Mechanism of Action, H1 2015 104 Number of Products by Stage and Route of Administration, H1 2015 109 Number of Products by Stage and Molecule Type, H1 2015 111 Epilepsy Therapeutics - Recent Pipeline Updates, H1 2015 265 Epilepsy - Dormant Projects, H1 2015 311 Epilepsy - Dormant Projects (Contd..1), H1 2015 312 Epilepsy - Dormant Projects (Contd..2), H1 2015 313 Epilepsy - Dormant Projects (Contd..3), H1 2015 314 Epilepsy - Dormant Projects (Contd..4), H1 2015 315 Epilepsy - Dormant Projects (Contd..5), H1 2015 316 Epilepsy - Discontinued Products, H1 2015 317 Epilepsy - Discontinued Products (Contd..1), H1 2015 318
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
